[{"orgOrder":0,"company":"Kaida BioPharma","sponsor":"Northway Biotechpharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"LITHUANIA","productType":"Other Large Molecule","year":"2025","type":"Agreement","leadProduct":"KAD101","moa":"Prolactin receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Kaida BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kaida BioPharma \/ Kaida BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Kaida BioPharma \/ Kaida BioPharma"}]

Find Clinical Drug Pipeline Developments & Deals by Kaida BioPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Hospitalar
                          Not Confirmed
                          Hospitalar
                          Not Confirmed

                          Details : Under the agreement, Northway will initiate the production of Kaida's lead product candidate, KAD101, which is being evaluated for the treatment of ovarian cancer.

                          Product Name : KAD101

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          May 21, 2025

                          Lead Product(s) : KAD101

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Northway Biotechpharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank